Pharmaceutical company Moderna — cofounded by a Cornell-educated medical pioneer — announced promising results in its development of a coronavirus vaccine on Nov. 16. With a vaccine efficacy rate of 94.1 percent, Moderna has emerged as one of the front ...

The stock soared more than 700% through 2020 and into the first weeks of 2021, and peak vaccine sales reached more than $18 billion for the 2022 full year. But, as demand for coronavirus vaccines waned during later stages of the pandemic,

WASHINGTON (WCSC) - Sunday marks five years since Moderna’s COVID-19 vaccine was found to be 95.4% effective in its clinical trial. The company announced on Nov. 16, 2020, a major breakthrough in the effort to combat the coronavirus pandemic. Data from ...

Lonza confident on 2020 target for Moderna vaccine Swiss locals watching, hoping for project success Swiss company focusing on drugs, selling chemicals unit New production lines at Lonza's site in Portsmouth, New Hampshire, aim to start making vaccine ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and MRNA and see which is better for you.

Once one of the biggest winners of the pandemic era, Moderna (MRNA) saw explosive growth as demand for its COVID-19 vaccine surged worldwide. Between 2020 and 2022, investors who put their belief in this unknown biotech saw astronomical returns.

While insurance will cover the shots, premiums could rise, the senator warned. Vermont Sen. Bernie Sanders, the incoming chair of the committee focused on health, on Tuesday called out Moderna for looking at a more-than-quadruple spike of its COVID-19 ...

When the Pfizer-BioNTech COVID-19 vaccine was authorized for emergency use by the Food and Drug Administration (FDA) in December 2020, President Donald Trump referred to it as a "medical miracle." "This is one of the greatest scientific accomplishments in ...